

Roche partners with Wellthy Therapeutics

October 30, 2018 | News

Roche to offer artificial intelligence-based digital diabetes coaching solution for people with type 2 diabetes to support improved self-management 24/7 in India.



Roche has announced its partnership with the digital health company Wellthy Therapeutics to offer users of the Accu-Chek Active system an innovative artificial intelligence-based digital diabetes coaching solution. Being a leader in diabetes management solutions worldwide, Roche will expand its integrated diabetes management offering through the collaboration with Wellthy Therapeutics. The joint offering of the two companies will encompass the trusted Accu-Chek Active blood glucose meter and the Wellthy Care app to new users. The bundle is being launched in the South and West Zones of India.

Speaking about the partnership, Rahul Kedia, Ad-Interim General Manager, Roche Diabetes Care India said, "India is home to the second largest number of people living with diabetes in the world, numbering about 73 million in 2017 as per the International Diabetes Federation. The figure is expected to almost double to 134 million by 2025 [i]. Moreover, factors such as limited doctor bandwidth to connect with patients outside the clinic, low adherence to care protocols and poor access to blood glucose monitoring makes it crucial to support people with diabetes in their daily therapy management routines to maximize health benefits. There is a real need for those patients to be able to monitor their blood glucose levels regularly and be supported in their efforts to keep their diabetes under control. With Wellthy's digital diabetes health coach, new Accu-Chek Active users can log blood glucose readings into the app to receive 24/7 guidance on understanding and managing their diabetes better. We firmly believe that this joint offering will help in improving the quality of life for Indians living with type 2 diabetes."

Wellthy Therapeutics is a digital therapeutics company that is inspiring and enabling patients to prevent, reverse and control their chronic disease. Its first digital therapeutic for Type II diabetes has been endorsed by the RSSDI, Asia's largest diabetes association. (RSSDI). Wellthy Therapeutics has published & presented real-world data for its diabetes therapeutic at the AADE Annual Conference in Baltimore, at the AACE 26th & 27th Annual Congresses in Austin and Boston, the ADA 77th & 78th Scientific sessions in San Diego and Orlando, the IDF Congress 2017 in Abu Dhabi, the ATTD 11th International Conference in Vienna, and the RSSDI 44th, 45th & 46th Annual Conferences in India. The company has been featured as a thought leader in diabetes care by the American Diabetes Association.

“Roche Diabetes Care shares our vision for digital therapeutic solutions that work alongside point of care diagnostics to achieve superior patient outcomes. We are excited about this partnership, as it gives people living with diabetes access to our clinically validated diabetes therapeutic to improve and manage their health. This partnership marks an important first step, in a larger shared vision to make a meaningful difference to the lives of millions of people living with this chronic disease”, said Abhishek Shah, Co-Founder & CEO of Wellthy Therapeutics.